- Home
- AMGN vs DE Comparison
AMGN vs DE Comparison
Compare AMGN & DE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- DE
- Stock Information
- Founded
- AMGN 1980
- DE 1837
- Country
- AMGN United States
- DE United States
- Employees
- AMGN N/A
- DE N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- DE Industrial Machinery/Components
- Sector
- AMGN Health Care
- DE Industrials
- Exchange
- AMGN Nasdaq
- DE Nasdaq
- Market Cap
- AMGN 141.6B
- DE 117.5B
- IPO Year
- AMGN N/A
- DE N/A
- Fundamental
- Price
- AMGN $272.11
- DE $455.54
- Analyst Decision
- AMGN Buy
- DE Buy
- Analyst Count
- AMGN 22
- DE 18
- Target Price
- AMGN $324.05
- DE $443.67
- AVG Volume (30 Days)
- AMGN 3.5M
- DE 1.2M
- Earning Date
- AMGN 02-04-2025
- DE 02-13-2025
- Dividend Yield
- AMGN 3.50%
- DE 1.42%
- EPS Growth
- AMGN N/A
- DE N/A
- EPS
- AMGN 7.83
- DE 25.62
- Revenue
- AMGN $32,534,000,000.00
- DE $51,532,000,000.00
- Revenue This Year
- AMGN $20.07
- DE N/A
- Revenue Next Year
- AMGN $3.59
- DE $6.01
- P/E Ratio
- AMGN $34.74
- DE $17.78
- Revenue Growth
- AMGN 21.25
- DE N/A
- 52 Week Low
- AMGN $253.30
- DE $340.20
- 52 Week High
- AMGN $346.85
- DE $469.39
- Technical
- Relative Strength Index (RSI)
- AMGN 54.19
- DE 65.85
- Support Level
- AMGN $267.15
- DE $426.45
- Resistance Level
- AMGN $272.82
- DE $429.10
- Average True Range (ATR)
- AMGN 4.68
- DE 9.83
- MACD
- AMGN 2.37
- DE 2.99
- Stochastic Oscillator
- AMGN 75.60
- DE 96.89
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About DE Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.